Netherlands· NL-ffdc69f6d4ae
Maviret 50 mg/20 mg, granulaat in sachet
A glecaprevir and pibrentasvir product containing glecaprevir + pibrentasvir, registered in Netherlands by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 15 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Glecaprevir and pibrentasvir is registered in 15 of 19 countries.
Countries holding a registration under ATC J05AP57 (glecaprevir and pibrentasvir), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 10 of them publish a price we can compare per daily dose
Glecaprevir and pibrentasvir · ATC J05AP57
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- GLECAPREVIR + PIBRENTASVIR
- Manufacturer
- AbbVie Deutschland GmbH & Co. KG
- Country
- Netherlands (NL)
- ATC code
- J05AP57
- ATC class
- Glecaprevir and pibrentasvir
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/17/1213
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Glecaprevir and pibrentasvir in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesMavyretAbbVie Inc.
- United KingdomGlecaprevir 100mg / Pibrentasvir 40mg tabletsAbbVie Ltd
- SpainMAVIRET 100 MG/40 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAbbvie Deutschland Gmbh & Co. Kg
- FinlandMaviretAbbVie Deutschland GmbH&Co.KG
- FranceMAVIRET 100 mg/40 mg, comprimé pelliculéABBVIE DEUTSCHLAND (ALLEMAGNE)
- CanadaMAVIRETABBVIE CORPORATION
- IcelandMaviretAbbVie Deutschland GmbH & Co. KG
- IrelandMaviret 100 mg/40 mg film-coated tabletsAbbVie Deutschland GmbH & Co. KG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Glecaprevir/Pibrentasvir Abbvie
- Iceland · Maviret
- Liechtenstein · Maviret
- Norway · Maviret
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d893a4b1-273a-48b4-aebf-a7ec2af77a88 GET /v1/drugs/d893a4b1-273a-48b4-aebf-a7ec2af77a88?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Granulaat",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/maviret-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Glecaprevir and pibrentasvir",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp126466",
"excipients": [
"COPOVIDON (E 1208)",
"CROSCARMELLOSE NATRIUM (E 468)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"IJZEROXIDE GEEL (E 172)",
"IJZEROXIDE ROOD (E 172)",
"LACTOSE 1-WATER",
"MACROGOL 3350",
"NATRIUMSTEARYLFUMARAAT",
"PROPYLEENGLYCOLMONOCAPRILAAT",
"SILICIUMDIOXIDE (E 551)"
],
"substances": [
"GLECAPREVIR",
"PIBRENTASVIR"
],
"leaflet_url": null,
"authorised_at": "2021/06/21",
"procedure_number": "EMEA/H/C/004430",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/17/1213",
"additional_monitoring": "N"
}See everything about glecaprevir and pibrentasvir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.